{
    "nct_id": "NCT05020678",
    "official_title": "A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies",
    "inclusion_criteria": "General:\n\nEastern Cooperative Oncology Group (ECOG) performance status ≤1\n\n• Disease Related:\n\n* Have a histologically or cytologically confirmed diagnosis of r/r B cell NHL or CLL or B-ALL as defined by WHO 2016 classification\n* Subjects who received prior CD19/CD20-directed therapy must have disease that remains CD19+ and/or CD20+ respectively\n* Have measurable disease\n* Have received ≥2 lines of therapy except subjects with MCL, CAR T Naïve cohorts and WM, who must have received at least 1 prior line of therapy\n* Have received a combination of an anti CD20 monoclonal antibody and cytotoxic chemotherapy for subjects with NHL\n* Received:\n\n  * BTKi for subjects with MCL, CLL/SLL, WM, and other indications where a BTKi is approved\n  * Venetoclax for subjects with CLL/SLL\n  * Tyrosine kinase inhibitor for subjects with Philadelphia chromosome (Ph+) B-ALL\n* Not responded or relapsed within 12 months of completion of their prior line of therapy, with the exception of a newly diagnosed Richter's transformation of CLL/SLL or other transformation of an indolent lymphoma, including from WM\n* Subjects must not have evidence of rapidly progressive disease that would preclude subject from completing at least 1 cycle of treatment.\n* Adequate organ function\n* White blood cell count of ≤20 × 109/L\n* Platelet count ≥30,000/uL\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "• Disease related:\n\n* Burkitt Lymphoma, primary central nervous system (CNS) lymphoma, Richter's transformation to Hodgkin lymphoma\n* Subjects with WM who underwent plasmapheresis <35 days prior to the first dose of NKX019\n* Subjects with NHL with any evidence of active CNS malignancy\n* Subjects with B-ALL who have extramedullary disease (EMD)\n* Subjects with any prior cellular therapy except subjects enrolling in selected cohorts who must have received prior CAR T therapy, recent HCT, or complications from HCT\n* Recent use of any cancer-directed therapy within protocol specified window prior to the first dose of NKX019\n* Residual toxicities ≥Grade 2 due to prior therapy\n* Other comorbid conditions and concomitant medications prohibited as per study protocol\n* Pregnant or lactating female",
    "miscellaneous_criteria": ""
}